The following article has been adapted for web. To read the complete version, please download the following:
Pre-implantation Diagnosis (PDF, 2.07MB)
New developments in technology not only raise new problems for consideration, they also raise new questions about old problems such as questions concerning the definition of life itself--its commencement and termination.
Sometimes the terms PID (Pre-implantation Diagnosis) and PGD are used almost interchangeably in Anglo-American states. Both are forms of pre-natal diagnosis.
Pre-natal diagnosis means testing for diseases or conditions in a foetus or embryo before it is born. Pre-implementation genetic diagnosis (PGD) involves genetically testing an embryo (or occasionally an ovum) in a laboratory.
To achieve this, couples need to have in vitro fertilisation (IVF) treatment followed by a genetic testing stage. The aim is to make it more likely that a baby will be born free from a particular condition (usually a disease). This is a means of avoiding pregnancy termination or the destruction of an embryo.
The embryo is grown in the laboratory for a couple of days until the cells have divided and the embryo consists of eight cells. At this time one or two of the cells are removed. If the genetic code associated with the condition is know, these cells can then be tested to see if they contain the faulty gene that causes a particular condition.
One or two of the embryos without a copy of the faulty gene can then be placed into the woman for continuation of its development. Any remaining unaffected embryos can be stored for later use as required. For some, this raises ethical concerns related to when human life begins, the sanctity of human life and the issue of selective abortion.
The value of PGD is that the probability of having a child affected by the harmful genetic condition is diminished, with no need for a pregnancy to be terminated.
Two main groups of patients currently use PGD:
1 Couples with a high risk of transmitting an inherited condition.
This may be due to a single defective gene or a chromosomal structural abnormality. In these situations the purpose of PGD is to identify embryos carrying such a defect and destroy them.
2 IVF couples whose embryos are screened for specific conditions.
There are a number of possible future medical uses. Possibilities include the diagnosis of late-onset diseases such as Alzheimer’s disease or predisposition to diseases such as obesity, diabetes, heart disease, asthma, cancer and even disabilities such as deafness.
PGD has the potential to screen for genetic issues unrelated to medical necessity.
Increasingly, PGD is being used for sex-selection. A 2006 survey found that 9% of US clinics provided this service. Half perform it only for ‘family balancing’.
There are concerns that PGD could be used as a form of eugenics (the development of particular selected races or populations), which can be defined as ‘the science of improving the population by the control of inherited qualities’. This places a negative value on people with certain conditions or qualities when it is seen as ‘socially desirable’ to prevent further development of certain foetuses.
The financial implications of medical interventions are often controversial. Some argue, for instance, that PGD could significantly reduce health care costs. Treatment of some genetic diseases can cost millions over the lifetime of a single individual. Some suggest that if births of these individuals could be avoided, then savings would be made.
For example, the lifetime treatment costs for someone with beta thalassemia in Britain are estimated at close to 200,000 pounds. This is likely to be considerably higher than the cost of tissue typing using PGD to select an appropriate ovum for development and subsequent stem cell transplantation from the resulting infant, although a precise costing is not available.
Issues for parents
Issues for offspring
A principle of the Human Fertilisation and Embryology Act is that the best interests of the child produced by assisted reproduction must be paramount. So, what is in the best interests of the child?
Issues for society
Is it harmful to society if families choose their children on the basis of their genetic makeup?
Other ethical issues to consider
Relying on the result of testing only one cell from a multi-cell embryo assumes that this cell is representative of the remainder of the embryo. This may not be the case. PGD may result in a false negative result leading to the acceptance of an abnormal embryo, or in a false positive result, leading to the rejection of a normal embryo.
Some people object to the discarding of unused embryos. They generally feel that human personhood starts at the instant of fertilisation.
Other objections concern the fact of selection itself, which may remove some positive traits that are unrecognised.
The Law Lords backed a 2003 Court of Appeal ruling that some couples undergoing fertility treatment could have their embryos screened to find tissue matches for seriously ill children. Advocates say the procedure will help save desperately ill children. Opponents fear it could lead to the creation of babies for spare parts.
Children have already been conceived to provide stem cells for their siblings use. PGD is used to select an embryo with the right genetic make-up to serve as a stem cell donor even in the absence of any family history of genetic disease.
The following could be asked: Who is harmed by allowing PGD to be performed solely for the benefit of a relative? Not the couple who wish to produce an embryo. Nor the child who would not otherwise have existed. Nor the person who receives the stem cell transplant that might save his or her life. It is argued that we must avoid the trap of interfering with individual liberty by preventing such procedures for no good reason, simply out of the ‘genophobia’ that grips much of society today.
Genetic manipulation that is intended to be restorative, recreating a damaged length of DNA or replacing an abnormal gene variant with a normal counterpart, seems consistent with normal medical practice, but enhancing gene therapy can also attempt to improve on the original design.
In general, doctors have agreed that if no treatment is available then it is unethical to perform screening tests on apparently healthy people.